These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10967224)

  • 1. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.
    Vyas SP; Sihorkar V
    Adv Drug Deliv Rev; 2000 Sep; 43(2-3):101-64. PubMed ID: 10967224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting.
    Vyas SP; Singh A; Sihorkar V
    Crit Rev Ther Drug Carrier Syst; 2001; 18(1):1-76. PubMed ID: 11326743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery.
    Rai S; Paliwal R; Vaidya B; Gupta PN; Mahor S; Khatri K; Goyal AK; Rawat A; Vyas SP
    Curr Med Chem; 2007; 14(19):2095-109. PubMed ID: 17691950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted breast cancer nanotherapeutics: options and opportunities with estrogen receptors.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas S
    Crit Rev Ther Drug Carrier Syst; 2012; 29(5):421-46. PubMed ID: 22876809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting strategies using endogenous cells and proteins.
    Parayath NN; Amiji MM
    J Control Release; 2017 Jul; 258():81-94. PubMed ID: 28483514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular delivery of drugs to macrophages.
    Mukhopadhyay A; Basu SK
    Adv Biochem Eng Biotechnol; 2003; 84():183-209. PubMed ID: 12934937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-induced drug targeting using novel peptide-ligand albumins.
    Meijer DK; Beljaars L; Molema G; Poelstra K
    J Control Release; 2001 May; 72(1-3):157-64. PubMed ID: 11389994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies.
    Varini K; Lécorché P; Sonnette R; Gassiot F; Broc B; Godard M; David M; Faucon A; Abouzid K; Ferracci G; Temsamani J; Khrestchatisky M; Jacquot G
    J Control Release; 2019 Nov; 314():141-161. PubMed ID: 31644939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics?
    Ogris M; Wagner E
    Hum Gene Ther; 2011 Jul; 22(7):799-807. PubMed ID: 21563983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.
    Xu S; Olenyuk BZ; Okamoto CT; Hamm-Alvarez SF
    Adv Drug Deliv Rev; 2013 Jan; 65(1):121-38. PubMed ID: 23026636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermal peptide delivery using colloidal carrier systems.
    Goebel A; Neubert RH
    Skin Pharmacol Physiol; 2008; 21(1):3-9. PubMed ID: 17912018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of herbal bioactives through folate receptors: a novel concept to enhance intracellular drug delivery in cancer therapy.
    Gupta A; Kaur CD; Saraf S; Saraf S
    J Recept Signal Transduct Res; 2017 Jun; 37(3):314-323. PubMed ID: 28095746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannosylated Constructs as a Platform for Cell-Specific Delivery of Bioactive Agents.
    Tiwari S
    Crit Rev Ther Drug Carrier Syst; 2018; 35(2):157-194. PubMed ID: 29717665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomimetic camouflage delivery strategies for cancer therapy.
    Asrorov AM; Gu Z; Li F; Liu L; Huang Y
    Nanoscale; 2021 May; 13(19):8693-8706. PubMed ID: 33949576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally active-targeted drug delivery systems for proteins and peptides.
    Li X; Yu M; Fan W; Gan Y; Hovgaard L; Yang M
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1435-47. PubMed ID: 24962803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in carbohydrate-decorated targeted drug/gene delivery.
    Zhang H; Ma Y; Sun XL
    Med Res Rev; 2010 Mar; 30(2):270-89. PubMed ID: 19626595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics.
    Webster DM; Sundaram P; Byrne ME
    Eur J Pharm Biopharm; 2013 May; 84(1):1-20. PubMed ID: 23313176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
    Tanaka T; Shiramoto S; Miyashita M; Fujishima Y; Kaneo Y
    Int J Pharm; 2004 Jun; 277(1-2):39-61. PubMed ID: 15158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Multivalent Ligands to Control Biological Interactions: From Vaccines and Cellular Effectors to Targeted Drug Delivery.
    Arsiwala A; Castro A; Frey S; Stathos M; Kane RS
    Chem Asian J; 2019 Jan; 14(2):244-255. PubMed ID: 30523672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.